Clinical Trial Contract Win

17 November 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington's Disease (HD). The total contract value is over £3.5m over four years.

Significant progress is being made in HD treatment research fuelling hope for patients. The disease is a rare, hereditary neurodegenerative disorder that leads to the progressive breakdown of nerve cells in the brain, affecting motor skills, cognitive function, mood, and emotional well-being. IXICO has deep expertise and experience in HD with the Company being recognised as a key participant in the HD ecosystem due to its advanced HD biomarker innovation, precise clinical trial management and state-of-the-art image analysis.

The positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive global expansion and growth.

Bram Goorden, CEO of IXICO, commented: "This is an important contract in terms of value and trial stage that further cements IXICO's position in the field. We are very proud to continue our support of the HD community, working with HD research consortia and pharmaceutical partners towards breakthrough treatments for patients in this devastating disease. As mentioned during the recent Capital Markets Day, I am greatly encouraged by biopharma's increased commitment to invest in rare neurological diseases and optimistic this will lead to disease modifying solutions in the near future."